161 related articles for article (PubMed ID: 36137139)
1. Pan-cancer gene expression analysis of tissue microarray using EdgeSeq oncology biomarker panel and a cross-comparison with HER2 and HER3 immunohistochemical analysis.
Inaki K; Shibutani T; Maeda N; Eppenberger-Castori S; Nicolet S; Kaneda Y; Koyama K; Qiu Y; Wakita K; Murakami M
PLoS One; 2022; 17(9):e0274140. PubMed ID: 36137139
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the EdgeSeq Precision Immuno-Oncology Panel for Gene Expression Profiling From Clinical Formalin-Fixed Paraffin-Embedded Tumor Specimens.
Shi Y; Ma X; Shen W; Liu T; Liang L; Liu S; Shen Z; Zhang Y; Zhang P
Front Cell Dev Biol; 2022; 10():899353. PubMed ID: 35712667
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.
Koutras A; Kalogeras KT; Wirtz RM; Alexopoulou Z; Bobos M; Zagouri F; Veltrup E; Timotheadou E; Gogas H; Pentheroudakis G; Pisanidis N; Magkou C; Christodoulou C; Bafaloukos D; Papakostas P; Aravantinos G; Pectasides D; Kalofonos HP; Fountzilas G
J Transl Med; 2015 May; 13():171. PubMed ID: 26021752
[TBL] [Abstract][Full Text] [Related]
4. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433
[TBL] [Abstract][Full Text] [Related]
5. HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients.
Bae SY; La Choi Y; Kim S; Kim M; Kim J; Jung SP; Choi MY; Lee SK; Kil WH; Lee JE; Nam SJ
Breast Cancer Res Treat; 2013 Jun; 139(3):741-50. PubMed ID: 23722313
[TBL] [Abstract][Full Text] [Related]
6. Comparing protein and mRNA expressions of the human epidermal growth factor receptor family in estrogen receptor-positive breast cancer.
Kurozumi S; Yamaguchi Y; Matsumoto H; Inoue K; Kurosumi M; Oyama T; Horiguchi J; Fujii T; Shirabe K
Med Mol Morphol; 2019 Jun; 52(2):90-98. PubMed ID: 30259117
[TBL] [Abstract][Full Text] [Related]
7. Reduced Expression of KRT17 Predicts Poor Prognosis in HER2
Tang S; Liu W; Yong L; Liu D; Lin X; Huang Y; Wang H; Cai F
Biomolecules; 2022 Aug; 12(9):. PubMed ID: 36139022
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study.
Koutras A; Lazaridis G; Koliou GA; Kouvatseas G; Christodoulou C; Pectasides D; Kotoula V; Batistatou A; Bobos M; Tsolaki E; Papadopoulou K; Pentheroudakis G; Papakostas P; Pervana S; Petraki K; Chrisafi S; Razis E; Psyrri A; Bafaloukos D; Kalogeras KT; Kalofonos HP; Fountzilas G
PLoS One; 2018; 13(12):e0207707. PubMed ID: 30521571
[TBL] [Abstract][Full Text] [Related]
9. Expression of PAM50 Genes in Lung Cancer: Evidence that Interactions between Hormone Receptors and HER2/HER3 Contribute to Poor Outcome.
Siegfried JM; Lin Y; Diergaarde B; Lin HM; Dacic S; Pennathur A; Weissfeld JL; Romkes M; Nukui T; Stabile LP
Neoplasia; 2015 Nov; 17(11):817-25. PubMed ID: 26678909
[TBL] [Abstract][Full Text] [Related]
10. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.
Bastien RR; Rodríguez-Lescure Á; Ebbert MT; Prat A; Munárriz B; Rowe L; Miller P; Ruiz-Borrego M; Anderson D; Lyons B; Álvarez I; Dowell T; Wall D; Seguí MÁ; Barley L; Boucher KM; Alba E; Pappas L; Davis CA; Aranda I; Fauron C; Stijleman IJ; Palacios J; Antón A; Carrasco E; Caballero R; Ellis MJ; Nielsen TO; Perou CM; Astill M; Bernard PS; Martín M
BMC Med Genomics; 2012 Oct; 5():44. PubMed ID: 23035882
[TBL] [Abstract][Full Text] [Related]
11. An Expression Signature as an Aid to the Histologic Classification of Non-Small Cell Lung Cancer.
Girard L; Rodriguez-Canales J; Behrens C; Thompson DM; Botros IW; Tang H; Xie Y; Rekhtman N; Travis WD; Wistuba II; Minna JD; Gazdar AF
Clin Cancer Res; 2016 Oct; 22(19):4880-4889. PubMed ID: 27354471
[TBL] [Abstract][Full Text] [Related]
12. Heregulin and HER3 are prognostic biomarkers in oropharyngeal squamous cell carcinoma.
Qian G; Jiang N; Wang D; Newman S; Kim S; Chen Z; Garcia G; MacBeath G; Shin DM; Khuri FR; Chen ZG; Saba NF
Cancer; 2015 Oct; 121(20):3600-11. PubMed ID: 26195293
[TBL] [Abstract][Full Text] [Related]
13. Pan-cancer analysis of N4-acetylcytidine adaptor THUMPD1 as a predictor for prognosis and immunotherapy.
Li K; Liu J; Yang X; Tu Z; Huang K; Zhu X
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34762107
[TBL] [Abstract][Full Text] [Related]
14. Reliable Gene Expression Profiling from Small and Hematoxylin and Eosin-Stained Clinical Formalin-Fixed, Paraffin-Embedded Specimens Using the HTG EdgeSeq Platform.
Qi Z; Wang L; Desai K; Cogswell J; Stern M; Lawson B; Kerkar SP; Vitazka P
J Mol Diagn; 2019 Sep; 21(5):796-807. PubMed ID: 31255795
[TBL] [Abstract][Full Text] [Related]
15. NRF1 motif sequence-enriched genes involved in ER/PR -ve HER2 +ve breast cancer signaling pathways.
Ramos J; Das J; Felty Q; Yoo C; Poppiti R; Murrell D; Foster PJ; Roy D
Breast Cancer Res Treat; 2018 Nov; 172(2):469-485. PubMed ID: 30128822
[TBL] [Abstract][Full Text] [Related]
16. A pan-cancer analysis of HER2 index revealed transcriptional pattern for precise selection of HER2-targeted therapy.
Li Z; Chen S; Feng W; Luo Y; Lai H; Li Q; Xiu B; Li Y; Li Y; Huang S; Zhu X
EBioMedicine; 2020 Dec; 62():103074. PubMed ID: 33161227
[TBL] [Abstract][Full Text] [Related]
17. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
18. Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer.
Li X; Xu Y; Ding Y; Li C; Zhao H; Wang J; Meng S
Mol Cancer; 2018 Aug; 17(1):113. PubMed ID: 30068375
[TBL] [Abstract][Full Text] [Related]
19. Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response.
Bosi C; Bartha Á; Galbardi B; Notini G; Naldini MM; Licata L; Viale G; Mariani M; Pistilli B; Ali HR; André F; Piras M; Callari M; Barreca M; Locatelli A; Viganò L; Criscitiello C; Pusztai L; Curigliano G; Győrffy B; Dugo M; Bianchini G
Eur J Cancer; 2023 Dec; 195():113379. PubMed ID: 37913680
[TBL] [Abstract][Full Text] [Related]
20. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
